文献速递皮肤肿瘤

反射式共聚焦显微镜检查对可疑病变诊断黑色素瘤准确性的影响:一项随机临床试验

Effect of Reflectance Confocal Microscopy for Suspect Lesions on Diagnostic Accuracy in Melanoma: A Randomized Clinical Trial.
PubMed 文献 · JAMA Dermatol · 2022-01-01

该随机临床试验纳入意大利3家皮肤科转诊中心的3165例患者,评估在标准治疗(临床和皮肤镜检查)基础上加用反射式共聚焦显微镜(RCM)对可疑病变的诊断准确性影响。与仅标准治疗相比,加用RCM与更高的阳性预测值(18.9 vs 33.3)、更低的良性恶性比(3.7:1.0 vs 1.8:1.0)以及需切除数降低43.4%(5.3 vs 3.0)相关。所有延迟诊断的黑色素瘤病变(n=15)厚度均小于0.5 mm。

要点

  • 加用RCM组阳性预测值为33.3,仅标准治疗组为18.9。
  • 加用RCM组良性恶性比为1.8:1.0,仅标准治疗组为3.7:1.0。
  • 加用RCM组需切除数为3.0,仅标准治疗组为5.3,降低43.4%。

核心结论

  • 在转诊中心实际临床决策中,对可疑病变加用RCM可减少不必要的切除,并保证在基线时切除侵袭性黑色素瘤。

研究设计与样本

  • 随机临床试验,纳入意大利3家皮肤科转诊中心2017年1月至2019年12月的3165例患者,平均(SD)随访9.6(6.9)个月(范围1.9-37.0个月)。
  • 通过皮肤镜确定的3165个可疑病变连续样本符合纳入条件(10例患者拒绝),诊断分析纳入3078例患者(48例失访,39例拒绝切除),数据于2021年4月至9月分析。
  • 患者按1:1随机分配至标准治疗(临床和皮肤镜评估)加用或不加用RCM,根据可用信息进行前瞻性临床决策(切除或随访)。

主要发现

  • 与仅标准治疗相比,加用RCM与更高的阳性预测值相关(18.9 vs 33.3)。
  • 与仅标准治疗相比,加用RCM与更低的良性恶性比相关(3.7:1.0 vs 1.8:1.0)。
  • 与仅标准治疗相比,加用RCM与需切除数降低43.4%相关(5.3 vs 3.0)。
  • 所有延迟诊断的黑色素瘤病变(n=15)厚度均小于0.5 mm。

关键数值与推荐

  • 阳性预测值:仅标准治疗组18.9 vs 加用RCM组33.3。
  • 良性恶性比:仅标准治疗组3.7:1.0 vs 加用RCM组1.8:1.0。
  • 需切除数:仅标准治疗组5.3 vs 加用RCM组3.0,降低43.4%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Previous systematic reviews and meta-analyses have concluded that given data paucity, a comparison of reflectance confocal microscopy (RCM) with dermoscopy is complex. They recommend comparative prospective studies in a real-world setting of suspect lesions. OBJECTIVE: To test the hypothesis that RCM reduces unnecessary lesion excision by more than 30% and identifies all melanoma lesions thicker than 0.5 mm at baseline. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial included 3165 patients enrolled from 3 dermatology referral centers in Italy between January 2017 and December 2019, with a mean (SD) follow-up of 9.6 (6.9) months (range, 1.9-37.0 months). The consecutive sample of 3165 suspect lesions determined through dermoscopy were eligible for inclusion (10 patients refused). Diagnostic analysis included 3078 patients (48 lost, 39 refused excision). Data were analyzed between April and September 2021. INTERVENTIONS: Patients were randomly assigned 1:1 to standard therapeutic care (clinical and dermoscopy evaluation) with or without adjunctive RCM. Information available guided prospective clinical decision-making (excision or follow-up). MAIN OUTCOMES AND MEASURES: Hypotheses were defined prior to study initiation. All lesions excised (baseline and follow-up) were registered, including histopathological diagnoses/no change at dermoscopy follow-up (with or without adjunctive RCM). Number needed to excise (total number of excised lesions/number of melanomas) and Breslow thickness of delayed diagnosed melanomas were calculated based on real-life, prospective, clinical decision-making. RESULTS: Among the 3165 participants, 1608 (50.8%) were male, and mean (SD) age was 49.3 (14.9) years. When compared with standard therapeutic care only, adjunctive RCM was associated with a higher positive predictive value (18.9 vs 33.3), lower benign to malignant ratio (3.7:1.0 vs 1.8:1.0), and a number needed to excise reduction of 43.4% (5.3 vs 3.0). All lesions (n = 15) with delayed melanoma diagnoses were thinner than 0.5 mm. CONCLUSIONS AND RELEVANCE: This randomized clinical trial shows that adjunctive use of RCM for suspect lesions reduces unnecessary excisions and assures the removal of aggressive melanomas at baseline in a real-life, clinical decision-making application for referral centers with RCM. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04789421.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Pellacani G, Farnetani F, Ciardo S, et al. Effect of Reflectance Confocal Microscopy for Suspect Lesions on Diagnostic Accuracy in Melanoma: A Randomized Clinical Trial. JAMA Dermatol. 2022. PMID: 35648432. doi:10.1001/jamadermatol.2022.1570

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。